Compare Ascendis Pharma A/S (ASND) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs MakeMyTrip Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while MakeMyTrip Ltd trades at $58.5 (market cap $5.56B). The key difference: Ascendis Pharma A/S is far larger — about 3.2× MakeMyTrip Ltd's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | MMYT | |
|---|---|---|
Market Cap | $17.74B | $5.56B |
Sector | Health | Technology |
52-Week High | $277.18 | $103.21 |
52-Week Low | $163.32 | $36.30 |
Enterprise Value | $18.11B | $6.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MMYT trades at $58.62, up 1.03% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.25 exceeding expectations. Revenue reached $978.34 million in 2025, though net income margin is projected to narrow to 4.96% in 2026. Analyst consensus is strongly positive with 72.73% buy ratings. Recent news highlights temporary travel disruptions but maintains confidence in long-term growth.
The outlook remains favorable given consistent earnings outperformance and robust analyst support, but risks include projected margin compression and rising debt levels. Investors should weigh strong operational cash flow against potential volatility from travel industry headwinds and increasing liabilities in the coming year.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
